Equities research analysts expect Regulus Therapeutics Inc (NASDAQ:RGLS) to post earnings per share of ($0.37) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Regulus Therapeutics’ earnings. Regulus Therapeutics posted earnings per share of ($1.68) in the same quarter last year, which suggests a positive year-over-year growth rate of 78%. The company is scheduled to issue its next quarterly earnings report on Wednesday, March 13th.
According to Zacks, analysts expect that Regulus Therapeutics will report full year earnings of ($4.99) per share for the current fiscal year. For the next year, analysts anticipate that the company will post earnings of ($4.97) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Regulus Therapeutics.
A number of research analysts have recently issued reports on the company. Wedbush set a $2.00 target price on Regulus Therapeutics and gave the company a “hold” rating in a research report on Friday, January 25th. Zacks Investment Research lowered Regulus Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 11th. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. The company presently has an average rating of “Hold” and an average price target of $1.38.
In other Regulus Therapeutics news, Director Stelios Papadopoulos bought 116,401 shares of the firm’s stock in a transaction dated Thursday, December 27th. The shares were purchased at an average price of $0.97 per share, for a total transaction of $112,908.97. Following the transaction, the director now directly owns 758,672 shares of the company’s stock, valued at approximately $735,911.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 5.40% of the company’s stock.
A hedge fund recently raised its stake in Regulus Therapeutics stock. Renaissance Technologies LLC boosted its position in Regulus Therapeutics Inc (NASDAQ:RGLS) by 396.3% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 595,501 shares of the biopharmaceutical company’s stock after purchasing an additional 475,512 shares during the quarter. Renaissance Technologies LLC owned about 6.82% of Regulus Therapeutics worth $118,000 at the end of the most recent reporting period.
Shares of NASDAQ:RGLS opened at $1.30 on Monday. Regulus Therapeutics has a 1 year low of $0.80 and a 1 year high of $10.68. The company has a market cap of $11.29 million, a PE ratio of -0.11 and a beta of 2.24.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
See Also: Buyback
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.